Amyotrophic lateral sclerosis: Early contributions of Jean‐Martin Charcot

@article{Goetz2000AmyotrophicLS,
  title={Amyotrophic lateral sclerosis: Early contributions of Jean‐Martin Charcot},
  author={Christopher G. Goetz},
  journal={Muscle \& Nerve},
  year={2000},
  volume={23}
}
  • C. Goetz
  • Published 1 March 2000
  • Psychology, Medicine
  • Muscle & Nerve
Amyotrophic lateral sclerosis is historically an important entity because its manifestations involve distinct signs that can be correlated with gray and white matter lesions at specific sites within the central nervous system. Working at the end of the nineteenth century, the celebrated neurologist, Jean‐Martin Charcot, used this disorder as a prototypic example of the power of his research method, termed “méthode anatomoclinique.” Using clinical cases and autopsy material, he showed how… 

Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis.

The definition of the clinicopathological entity of amyotrophic lateral sclerosis evolved over half a century, and several aspects of the exquisite clinical histories documented as part of both studies, one by Charles Bland Radcliffe, resonate with contemporary debates concerning the evolution of disease in amyotoxicity.

Charcot identifies and illustrates amyotrophic lateral sclerosis

The technique used by Charcot and his interpretation of the microscopic pictures, as exposed in his lessons, are discussed.

How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot.

  • L. Rowland
  • Medicine, Psychology
    Archives of neurology
  • 2001
A myotrophic lateral sclerosis (ALS) occupies a unique place in the history of human disease in general and in neurological disease in particular. Charcot was the one who deduced the relationship

Phenotypic variability and its pathological basis in amyotrophic lateral sclerosis

Underlying region‐specific cellular vulnerability may exist in the upper and lower motor neurons and frontotemporal system in patients with ALS, and this vulnerability may be linked to the macroscopic propensities of the sites of onset, and may also determine the direction and rate of progression of the lesions.

Chapter 16 Primary lateral sclerosis.

  • A. Eisen
  • Psychology, Medicine
    Handbook of clinical neurology
  • 2007

Amyotrophic lateral sclerosis: disease state overview.

  • D. Hulisz
  • Psychology, Medicine
    The American journal of managed care
  • 2018
The best practices for the management of ALS include an interdisciplinary approach aimed at addressing the physical and psychological needs and desires of patients and their families and caregivers.

J.-M. Charcot and simulated neurologic disease

  • C. Goetz
  • Medicine, Psychology
    Neurology
  • 2007
Background: Neurologists have long wrestled with the diagnosis of elaborated or feigned disease. Studies have not focused on early techniques utilized to diagnose malingering. Objective: To analyze

History of Neurology Franc¸ois-Amilcar Aran (1817–1861) and the recognition of spinal muscular atrophy

Jean-Martin Charcot coined the term Duchenne-Aran atrophy. The inversion of names compared to standard practice shows the respect Charcot had for Guillaume Duchenne de Boulogne, who had encouraged

The motor cortex and amyotrophic lateral sclerosis

Evidence derived from clinical, neuropathological, static, and functional imaging, and physiological studies, favors the occurrence of anterograde degeneration in ALS.
...

References

SHOWING 1-2 OF 2 REFERENCES

A Manual of Diseases of the Nervous System

  • W. Gowers
  • Medicine
    Edinburgh Medical Journal
  • 1887
The present work is a most painstaking attempt to systematize and elucidate the vast mass of facts which have been accumulated during the labours of recent years.